Safety and efficacy of an 8-week regimen of grazoprevir plus ruzasvir plus uprifosbuvir compared with grazoprevir plus elbasvir plus uprifosbuvir in participants without cirrhosis infected with hepatitis C virus genotypes 1, 2, or 3 (C-CREST-1 and C-CREST-2, part A): two randomised, phase 2, open-label trials Journal Articles Refereed uri icon

Overview

Authors

  • Authorship

    • GANE EJ
    • LAURSEN AL
    • GERSTOFT J
    • GAO W
    • HUANG H-C
    • FITZGERALD B
    • FERNSLER D
    • LI JJ
    • GRANDHI A
    • LIU H
    • SU F-H
    • PIANKO S
    • WAN S
    • ZENG Z
    • CHEN H-L
    • DUTKO FJ
    • NGUYEN B-YT
    • WAHL J
    • ROBERTSON MN
    • BARR E
    • YEH WW
    • PLANK RM
    • ROBERTS SK
    • BUTTERTON JR
    • ESTEBAN R
    • DR Alex Thompson
    • ZEUZEM S
    • ZUCKERMAN E
    • BEN-ARI Z
    • FOSTER GR
    • AGARWAL K

Time

Date/time value

  • 2017

Identity

Digital Object Identifier (DOI)

  • 10.1016/S2468-1253(17)30159-0

Additional Document Info

Parent Title

  • LANCET GASTROENTEROLOGY & HEPATOLOGY

Volume

  • 2

Issue

  • 11

Publisher

  • Academic Press